1. |
Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet, 2018, 391(10140): 2619-2630.
|
2. |
Parajuli S, Mandelbrot DA, Aziz F, et al. Characteristics and outcomes of kidney transplant recipients with a functioning graft for more than 25 years. Kidney Dis (Basel), 2018, 4(4): 255-261.
|
3. |
Skulratanasak P, Mahamongkhonsawata J, Chayakulkeereeb M, et al. BK virus infection in Thai kidney transplant recipients: a single-center experience. Transplant Proc, 2018, 50(4): 1077-1079.
|
4. |
Zabana Y, Rodríguez L, Lobatón T, et al. Relevant infections in inflammatory bowel disease, their relationship with immunosuppressive therapy and their effects on disease mortality. J Crohns Colitis, 2019, 13(7): 828-837.
|
5. |
周易, 姚雷雨, 于哲, 等. BK多瘤病毒在肾移植受者中的感染特征. 南方医科大学学报, 2019, 39(1): 126-130.
|
6. |
齐隽, 闵志廉, 常继伟, 等. 肾移植后免疫抑制用药方案与移植肾长期存活的关系. 中华器官移植杂志, 2000, 21(5): 288-290.
|
7. |
Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs, 2013, 15(4): 303-310.
|
8. |
李阳波, 卢奕, 许亚宏, 等. 肾移植术后免疫抑制剂联合应用的方案优化研究. 西南国防医药, 2017, 27(2): 146-148.
|
9. |
薛武军. 器官移植免疫抑制治疗策略. 实用器官移植电子杂志, 2015, 3(5): 268-271.
|
10. |
卢一平. 肾移植受者糖尿病、高血压和血脂异常防治策略. 中华移植杂志(电子版), 2010, (3): 182-186.
|
11. |
Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1. Transplantation, 2003, 75(6): 1625-1626.
|
12. |
Hardinger KL, Bohl DL, Schnitzler MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation, 2005, 80(1): 41-46.
|
13. |
Ekberg H, Bernasconi C, Nöldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant, 2010, 25(6): 2004-2010.
|
14. |
Park JB, Kim SJ, Oh HY, et al. Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study. Transpl Int, 2006, 19(6): 478-484.
|
15. |
Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant, 2007, 7(3): 595-608.
|
16. |
Torres A, Hernández D, Moreso F, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus. Kidney Int Rep, 2018, 3(6): 1304-1315.
|
17. |
Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol, 2002, 17(3): 141-149.
|
18. |
Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant, 2007, 7(6): 1506-1514.
|
19. |
White SA, Jain S, Williams ST, et al. Randomized trial comparing neoral and tacrolimus immunousuppression for recipients of renal transplants procured from different donor groups. Transplant Proc, 2000, 32(3): 600.
|
20. |
Wissing KM, Abramowicz D, Weekers L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. Am J Transplant, 2018, 18(7): 1726-1734.
|
21. |
Yang HC, Holman MJ, Langhoff E, et al. Tacrolimus/" low-dose” mycophenolate mofetil versus microemulsion cyclosporine/" low-dose” mycophenolate mofetil after kidney transplantation—1-year follow-up of a prospective, randomized clinical trial. Transplant Proc, 1999, 31(1-2): 1121-1124.
|
22. |
陈国栋, 陈立中, 王长希, 等. 他克莫司与环孢素A在高致敏肾移植受者中的应用比较. 中华器官移植杂志, 2008, 29(4): 222-224.
|
23. |
戴澄, 王平, 张新涛, 等. 移植肾急性排斥反应彩色多普勒超声诊断的临床价值. 中国组织工程研究与临床康复, 2009, 13(53): 10427-10430.
|
24. |
Westall GP, Paraskeva MA, Snell GI. Antibody-mediated rejection. Curr Opin Organ Transplant, 2015, 20(5): 492-497.
|
25. |
Ishimura T, Fujisawa M, Isotani S, et al. Transforming growth factor-beta1 expression in early biopsy specimen predicts long-term graft function following pediatric renal transplantation. Clin Transplant, 2001, 15(3): 185-191.
|
26. |
He X, Johnston A. Risk factors for allograft failure in United Kingdom renal transplant recipients treated with cyclosporine A. Transplantation, 2005, 79(8): 953-957.
|
27. |
Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant, 1999, 13(3): 209-220.
|
28. |
Liu JY, You RX, Guo M, et al. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation. Am J Ther, 2016, 23(3): e810-e824.
|